Nakamura K, Takeda M, Tanaka T, Tanaka J, Kato Y, Nishinuma K, Nishimura T
Department of Neuropsychiatry, Osaka University Medical School, Japan.
Methods Find Exp Clin Pharmacol. 1992 Mar;14(2):141-9.
The level of anti-GFAP (glial fibrillary acidic protein) IgG antibody titer was assayed in sera of patients with Alzheimer's disease, multi-infarct dementia, and the age-matched control subjects. Significantly higher level of anti-CFAP titer was found in sera of Alzheimer's disease patients. The in vitro lymphocyte response was studied by stimulation with GFAP and interleukin 2 (IL-2). The lymphocytes of Alzheimer's disease patients showed higher proliferative response than those of the control by GFAP and IL-2 stimulation. The IgG secretion by lymphocytes from Alzheimer's disease patients was also stimulated by GFAP as well as by GFAP plus IL-2. The results demonstrate that the lymphocytes of Alzheimer's disease patients are more responsive to GFAP than those of the control subjects.
检测了阿尔茨海默病患者、多发梗死性痴呆患者以及年龄匹配的对照受试者血清中抗胶质纤维酸性蛋白（GFAP）IgG抗体滴度。结果发现，阿尔茨海默病患者血清中的抗GFAP滴度显著更高。通过用GFAP和白细胞介素2（IL-2）刺激来研究体外淋巴细胞反应。与对照组相比，GFAP和IL-2刺激使阿尔茨海默病患者的淋巴细胞表现出更高的增殖反应。GFAP以及GFAP加IL-2也刺激了阿尔茨海默病患者淋巴细胞分泌IgG。结果表明，与对照受试者相比，阿尔茨海默病患者的淋巴细胞对GFAP反应更强。
